Marktprognose für Pharmakokinetikdienstleistungen im asiatisch-pazifischen Raum bis 2031 – Regionale Analyse – nach Arzneimitteltyp (kleine Moleküle, große Moleküle und Impfstoffe), Servicetyp (präklinische ADME- und Humanstudien, PK/PD-Analyse und -Berichterstattung, Dosierungssimulationen, Risikoanalyse und andere), therapeutische Anwendung (Onkologie, Infektionskrankheiten, neurologische Erkrankungen, Autoimmunerkrankungen, gynäkologische Erkrankungen, Herz-Kreislauf-Erkrankungen, Atemwegserkrankungen und andere) und Endbenutzer (Pharma- und Biotechnologieunternehmen, Auftragsforschungsinstitute und andere)
Die zunehmende Einführung von In-Vivo- und In-Vitro-Modellen zum Verständnis der Variabilität in der Pharmakokinetik beflügelt den Markt für Pharmakokinetikdienstleistungen im asiatisch-pazifischen Raum.
Das Sammeln und Verarbeiten riesiger pharmakokinetischer Daten, die bei der Arzneimittelherstellung anfallen, sind teure, mühsame und zeitaufwändige Aufgaben. Der arbeits- und kostenintensive Charakter dieser Aufgaben unterstreicht den Bedarf an Modellen wie pharmakokinetischen Simulationsmodellen und in vitro-in vivo pharmakokinetischen Korrelationsmodellen (IVIVC) zur Vorhersage pharmakokinetischer Parameter. Das pharmakokinetische Simulationsmodell ist ein Tool, das die Arzneimittelkinetik in der Lebensumgebung unter bestimmten Bedingungen mithilfe rechnerischer und mathematischer Modelle interpretiert. Darüber hinaus ist das IVIVC-Modell ein grundlegender Teil des Arzneimittelentdeckungsprozesses. Die Analyse von PK/PD-Vorhersagen in den frühen Phasen der Arzneimittelentwicklung ist für Lead-Optimierungsstrategien und auch zur weiteren Reduzierung der Ausfallraten erforderlich. Bei der Entwicklung neuer In-vitro- und In-vivo-Strategien zur Verbesserung und Charakterisierung pharmakokinetischer Eigenschaften wurden erhebliche Fortschritte erzielt. IVIVC-Modelle werden als kostengünstige Alternative zur Bewertung der biopharmazeutischen Eigenschaften vorgeschlagen, die die Bioverfügbarkeit von Arzneimitteln und ihre Anwendung analysieren. Daher wird erwartet, dass solche In-vivo- und In-vitro-Modelle in naher Zukunft lukrative Möglichkeiten für den Markt für Pharmakokinetikdienstleistungen im asiatisch-pazifischen Raum bieten werden.
Überblick über den Markt für Pharmakokinetikdienstleistungen im asiatisch-pazifischen Raum
Das Wachstum des Marktes für Pharmakokinetikdienstleistungen im asiatisch-pazifischen Raum in China ist in erster Linie auf den etablierten Pharmamarkt, steigende F&E-Ausgaben von Pharma- und Biopharmaunternehmen, eine steigende Zahl klinischer Studien aufgrund niedrigerer Betriebskosten und günstige Regulierungsrichtlinien zurückzuführen. Laut dem 2023 veröffentlichten EFPIA-Bericht stiegen die F&E-Ausgaben der Pharmaunternehmen in China von 10.814,23 Millionen US-Dollar im Jahr 2020 auf 12.989,23 Millionen US-Dollar im Jahr 2021. China hat den zweitgrößten Pharmamarkt der Welt. Die übermäßige Bevölkerung des Landes, gepaart mit einem Anstieg der Fälle verschiedener nicht übertragbarer und ansteckender Krankheiten, treibt den Bedarf an neuen Arzneimittelmolekülen an, was China zu einem wichtigen Markt im asiatisch-pazifischen Raum macht.
Marktumsatz und Prognose für Pharmakokinetikdienstleistungen im asiatisch-pazifischen Raum bis 2031 (in Millionen US-Dollar)
Marktsegmentierung für Pharmakokinetikdienstleistungen im asiatisch-pazifischen Raum
Der Markt für Pharmakokinetikdienstleistungen im asiatisch-pazifischen Raum ist nach Arzneimitteltyp, Dienstleistungstyp, therapeutischer Anwendung, Endverbraucher und Land kategorisiert.
Basierend auf dem Arzneimitteltyp ist der Markt für Pharmakokinetikdienstleistungen im asiatisch-pazifischen Raum in kleine Moleküle, große Moleküle und Impfstoffe segmentiert. Das Segment der kleinen Moleküle hatte 2023 den größten Marktanteil.
Nach Dienstleistungsart ist der Markt für Pharmakokinetikdienstleistungen im asiatisch-pazifischen Raum in präklinische ADME- und Humanstudien, PK/PD-Analyse und -Berichterstattung, Dosierungssimulationen, Risikoanalysen und andere unterteilt. Das Segment präklinische ADME- und Humanstudien hatte 2023 den größten Marktanteil.
Nach therapeutischer Anwendung ist der Markt für Pharmakokinetikdienstleistungen im asiatisch-pazifischen Raum in Onkologie, Infektionskrankheiten, neurologische Erkrankungen, Autoimmunerkrankungen, gynäkologische Erkrankungen, Herz-Kreislauf-Erkrankungen, Atemwegserkrankungen und andere unterteilt. Das Segment Onkologie hatte 2023 den größten Marktanteil.
Nach Endbenutzer ist der Markt für Pharmakokinetikdienstleistungen im asiatisch-pazifischen Raum in Pharma- und Biotechnologieunternehmen, Auftragsforschungsinstitute und andere unterteilt. Das Segment der Vertragsforschungsinstitute hatte 2023 den größten Marktanteil.
Nach Ländern ist der Markt für Pharmakokinetikdienstleistungen im asiatisch-pazifischen Raum in China, Japan, Indien, Australien, Südkorea und den Rest des asiatisch-pazifischen Raums unterteilt. Japan dominierte 2023 den Marktanteil der Pharmakokinetikdienstleistungen im asiatisch-pazifischen Raum.
Allucent; Certara Inc.; Charles River Laboratories International Inc; Eurofins Scientific SE; PACIFIC BIOLABS; Parexel International Corp; SGS SA; Shanghai Medicilon Inc.; und Thermo Fisher Scientific Inc. sind einige der führenden Unternehmen auf dem Markt für Pharmakokinetikdienstleistungen im asiatisch-pazifischen Raum.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Pharmacokinetics Services Market - Key Market Dynamics
4.1 Market Drivers
4.1.1 Rising Prevalence of Chronic and Infectious Diseases
4.1.2 Expanding Range of Application of Pharmacokinetic Studies
4.1.3 Outsourcing of Pharmacokinetics Services to CROs
4.2 Market Restraints
4.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
4.3 Market Opportunities
4.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
4.4 Future Trend
4.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
4.5 Impact of Drivers and Restraints:
5. Pharmacokinetics Services Market - Asia Pacific Analysis
5.1 Asia Pacific Pharmacokinetics Services Market Overview
5.2 Asia Pacific Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
6. Asia Pacific Pharmacokinetics Services Market Analysis - by Drug Type
6.1 Overview
6.2 Small Molecule
6.2.1 Overview
6.2.2 Small Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.3 Large Molecule
6.3.1 Overview
6.3.2 Large Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.4 Vaccines
6.4.1 Overview
6.4.2 Vaccines: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7. Asia Pacific Pharmacokinetics Services Market Analysis - by Service Type
7.1 Overview
7.2 Pre-Clinical ADME and Human Studies
7.2.1 Overview
7.2.2 Pre-Clinical ADME and Human Studies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.3 PK/PD Analysis and Reporting
7.3.1 Overview
7.3.2 PK/PD Analysis and Reporting: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Dosing Simulations
7.4.1 Overview
7.4.2 Dosing Simulations: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Risk Analysis
7.5.1 Overview
7.5.2 Risk Analysis: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8. Asia Pacific Pharmacokinetics Services Market Analysis - by Therapeutic Application
8.1 Oncology
8.1.1 Overview
8.1.2 Oncology: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Infectious Diseases
8.2.1 Overview
8.2.2 Infectious Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Neurological Disorders
8.3.1 Overview
8.3.2 Neurological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Autoimmune Diseases
8.4.1 Overview
8.4.2 Autoimmune Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Gynecological Disorders
8.5.1 Overview
8.5.2 Gynecological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Cardiovascular Diseases
8.6.1 Overview
8.6.2 Cardiovascular Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.7 Respiratory Disorders
8.7.1 Overview
8.7.2 Respiratory Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9. Asia Pacific Pharmacokinetics Services Market Analysis - by End User
9.1 Pharmaceutical and Biotechnology Companies
9.1.1 Overview
9.1.2 Pharmaceutical and Biotechnology Companies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Contract Research Organization
9.2.1 Overview
9.2.2 Contract Research Organization: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Others
9.3.1 Overview
9.3.2 Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10. Asia Pacific Pharmacokinetics Services Market - Country Analysis
10.1 Asia Pacific
10.1.1 Asia Pacific Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
10.1.1.1 China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.3 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.1.4 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.1.5 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.1.6 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
10.1.1.2 Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.3 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.2.4 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.2.5 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.2.6 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
10.1.1.3 India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.3 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.3.4 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.3.5 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.3.6 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
10.1.1.4 Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.3 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.4.4 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.4.5 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.4.6 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
10.1.1.5 South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.5.1 Overview
10.1.1.5.2 South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.5.3 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.5.4 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.5.5 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.5.6 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
10.1.1.6 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.6.1 Overview
10.1.1.6.2 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.6.3 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.6.4 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.6.5 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.6.6 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
11. Company Profile
11.1 Charles River Laboratories International Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eurofins Scientific SE
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Certara Inc.
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.4 Parexel International Corp
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Thermo Fisher Scientific Inc.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Allucent
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 PACIFIC BIOLABS
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 SGS SA
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Shanghai Medicilon Inc.
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms for Pharmacokinetic Services Market
?
List of Tables
Table 1. Asia Pacific Pharmacokinetics Services Market Segmentation
Table 2. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 3. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 4. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 5. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 6. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 7. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 8. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 9. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 10. R&D Expenditure of Indian Companies, 2018-2020 (US$ Million)
Table 11. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 12. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 13. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 14. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 15. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 16. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 17. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 18. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 19. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 20. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 21. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 22. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 23. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 24. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 25. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 26. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 27. Glossary of Terms
?
List of Figures
Figure 1. Asia Pacific Pharmacokinetics Services Market Segmentation, by Country
Figure 2. Asia Pacific Pharmacokinetics Services Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
Figure 5. Asia Pacific Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)
Figure 6. Small Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 7. Large Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 8. Vaccines: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 9. Asia Pacific Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)
Figure 10. Pre-Clinical ADME and Human Studies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 11. PK/PD Analysis and Reporting: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 12. Dosing Simulations: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 13. Risk Analysis: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 14. Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 15. Asia Pacific Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)
Figure 16. Oncology: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 17. Infectious Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 18. Neurological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 19. Autoimmune Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 20. Gynecological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 21. Cardiovascular Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 22. Respiratory Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 23. Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 24. Asia Pacific Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)
Figure 25. Pharmaceutical and Biotechnology Companies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 26. Contract Research Organization: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 27. Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 28. Asia Pacific Pharmacokinetics Services Market - Revenue by Key Countries 2023 (US$ Million)
Figure 29. Asia Pacific Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 30. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 31. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 32. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 33. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 34. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 35. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- Allucent
- Certara Inc.
- Charles River Laboratories International Inc
- Eurofins Scientific SE
- PACIFIC BIOLABS
- Parexel International Corp
- SGS SA
- Shanghai Medicilon Inc.
- Thermo Fisher Scientific Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific pharmacokinetics services market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific pharmacokinetics services market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific pharmacokinetics services market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.